User login
Key clinical point: Arterial input function and quality were similar for HCC patients who received either gadoxetate disodium or gadobenate dimeglumine during the first 3 minutes after contrast injection during DCE-MRI.
Major finding: Measures of arterial input function quality, modelled, and model-free perfusion parameters were not significantly different for patients who received either gadoxetate disodium or gadobenate dimeglumine during the first 3 minutes after contrast injection during DCE-MRI; P values ranged from 0.054-0.932. However, patients in the gadoxetate disodium group showed significantly lower liver parenchymal flow and later liver enhancement (P < 0.001).
Study details: The data come from a prospective study of 66 adults with 83 hepatocellular carcinomas who underwent dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI).
Disclosures: The study was supported in part by the National Institutes of Health. The researchers had no financial conflicts to disclose.
Source: Stocker D et al. Eur Radiol. 2021 May 27. doi: 10.1007/s00330-021-08068-5.
Key clinical point: Arterial input function and quality were similar for HCC patients who received either gadoxetate disodium or gadobenate dimeglumine during the first 3 minutes after contrast injection during DCE-MRI.
Major finding: Measures of arterial input function quality, modelled, and model-free perfusion parameters were not significantly different for patients who received either gadoxetate disodium or gadobenate dimeglumine during the first 3 minutes after contrast injection during DCE-MRI; P values ranged from 0.054-0.932. However, patients in the gadoxetate disodium group showed significantly lower liver parenchymal flow and later liver enhancement (P < 0.001).
Study details: The data come from a prospective study of 66 adults with 83 hepatocellular carcinomas who underwent dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI).
Disclosures: The study was supported in part by the National Institutes of Health. The researchers had no financial conflicts to disclose.
Source: Stocker D et al. Eur Radiol. 2021 May 27. doi: 10.1007/s00330-021-08068-5.
Key clinical point: Arterial input function and quality were similar for HCC patients who received either gadoxetate disodium or gadobenate dimeglumine during the first 3 minutes after contrast injection during DCE-MRI.
Major finding: Measures of arterial input function quality, modelled, and model-free perfusion parameters were not significantly different for patients who received either gadoxetate disodium or gadobenate dimeglumine during the first 3 minutes after contrast injection during DCE-MRI; P values ranged from 0.054-0.932. However, patients in the gadoxetate disodium group showed significantly lower liver parenchymal flow and later liver enhancement (P < 0.001).
Study details: The data come from a prospective study of 66 adults with 83 hepatocellular carcinomas who underwent dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI).
Disclosures: The study was supported in part by the National Institutes of Health. The researchers had no financial conflicts to disclose.
Source: Stocker D et al. Eur Radiol. 2021 May 27. doi: 10.1007/s00330-021-08068-5.